Abstract:
PROBLEM TO BE SOLVED: To provide an antibody specifically bonding generally to hepatitis C virus(HCV), more particularly, a panel of a new hybridoma cell strain secreting a monoclonal antibody against HCV protein 33C and the use of the monoclonal antibody. SOLUTION: The present invention relates to a monoclonal antibody specifically bonding to HCV protein 33C and free from bonding potency to HCV protein C-100 and a core and to a hybridoma producing the monoclonal antibody and selected from the group consisting of A.T.C.C. deposit No. HB10594, HB10589, HB10607 and HB10600. It also relates to a method for the use of the monoclonal antibody e.g. for the detection of hepatitis C virus HCV 33C protein in a specimen and an assay kit containing the antibody.
Abstract:
PROBLEM TO BE SOLVED: To provide a highly specific and novel monoclonal antibody available for detecting a hepatitis C virus protein. SOLUTION: A monoclonal antibody not binding to hepatitis C virus C-100 protein and hepatitis C virus 33C protein and specifically binding to hepatitis C virus core protein, a hybridoma yielding the monoclonal antibody, a method for using the monoclonal antibody and an assay kit containing the antibody are provided.
Abstract:
The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Abstract:
The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.
Abstract:
The present disclosure relates to isolated antibodies that do not bind to brain natriuretic peptide that can be used as a reagent to reduce heterophilic interference in an immunoassay.